Zynex Inc (ZYXI) - Total Liabilities

Latest as of September 2025: $86.69 Million USD

Based on the latest financial reports, Zynex Inc (ZYXI) has total liabilities worth $86.69 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Zynex Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Zynex Inc - Total Liabilities Trend (1999–2024)

This chart illustrates how Zynex Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Zynex Inc.

Zynex Inc Competitors by Total Liabilities

The table below lists competitors of Zynex Inc ranked by their total liabilities.

Company Country Total Liabilities
VS Media Holdings Limited Class A Ordinary Shares
NASDAQ:VSME
USA $5.20 Million
Urban One
NASDAQ:UONE
USA $532.28 Million
Electromagnetic Geoservices ASA
OL:EMGS
Norway Nkr21.39 Million
SOLARTRON -NVDR- BA 1
F:TUU
Germany €1.05 Billion
Aminex PLC
STU:DOP
Germany €15.15 Million
Power REIT
NYSE MKT:PW
USA $21.75 Million
Redstone Resources Ltd
AU:RDS
Australia AU$1.14 Million
Gulf Marine Services PLC
LSE:GMS
UK GBX263.39 Million

Liability Composition Analysis (1999–2024)

This chart breaks down Zynex Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Zynex Inc (ZYXI) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.47 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.10 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.91 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Zynex Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Zynex Inc (1999–2024)

The table below shows the annual total liabilities of Zynex Inc from 1999 to 2024.

Year Total Liabilities Change
2024-12-31 $86.37 Million -4.85%
2023-12-31 $90.78 Million +68.13%
2022-12-31 $53.99 Million -9.03%
2021-12-31 $59.35 Million +241.71%
2020-12-31 $17.37 Million +101.39%
2019-12-31 $8.62 Million +25.24%
2018-12-31 $6.89 Million +71.00%
2017-12-31 $4.03 Million -48.98%
2016-12-31 $7.89 Million +1.62%
2015-12-31 $7.77 Million -7.33%
2014-12-31 $8.38 Million -32.26%
2013-12-31 $12.37 Million -10.69%
2012-12-31 $13.85 Million +18.97%
2011-12-31 $11.64 Million +54.87%
2010-12-31 $7.52 Million +69.21%
2009-12-31 $4.44 Million -26.06%
2008-12-31 $6.01 Million +68.93%
2007-12-31 $3.56 Million +140.24%
2006-12-31 $1.48 Million +63.79%
2005-12-31 $904.13K +54.10%
2004-12-31 $586.71K -34.16%
2003-12-31 $891.11K -7.29%
2002-12-31 $961.22K +1.34%
2001-12-31 $948.54K +27.97%
2000-12-31 $741.21K -607647.54%
1999-12-31 $-122.00 --

About Zynex Inc

NASDAQ:ZYXI USA Medical Distribution
Market Cap
$2.61 Million
Market Cap Rank
#29762 Global
#6063 in USA
Share Price
$0.09
Change (1 day)
+7.50%
52-Week Range
$0.03 - $1.59
All Time High
$25.72
About

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) dev… Read more